RDC-0313 + Buprenorphine + Placebo

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Substance-Related Disorders

Conditions

Substance-Related Disorders

Trial Timeline

Jan 1, 2010 → Jul 1, 2010

NCT ID

NCT01046539

About RDC-0313 + Buprenorphine + Placebo

RDC-0313 + Buprenorphine + Placebo is a phase 1 stage product being developed by Alkermes for Substance-Related Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01046539. Target conditions include Substance-Related Disorders.

What happened to similar drugs?

1 of 1 similar drugs in Substance-Related Disorders were approved

Approved (1) Terminated (0) Active (0)

✅naltrexone for extended release injectable suspensionAlkermesApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01046539	Phase 1	Completed	Jan 1, 2010	Jul 1, 2010	Substance-Related Disorders

Competing Products

1 competing product in Substance-Related Disorders

See all competitors

Product	Company	Stage	Hype Score
naltrexone for extended release injectable suspension	Alkermes	Approved	40